NXC-201 (Immix Biopharma Inc.) for Relapsed/Refractory Amyloid Light Chain Amyloidosis

A B-cell maturation antigen (BCMA)-targeted autologous T-cell therapy under investigation for the treatment of relapsed/refractory AL amyloidosis.